Cochrane Database of Systematic Reviews 2014
DOI: 10.1002/14651858.cd011281
|View full text |Cite
|
Sign up to set email alerts
|

Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
19
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(20 citation statements)
references
References 41 publications
1
19
0
Order By: Relevance
“…Several studies have demonstrated that the use of subcutaneous rapid-acting insulin analogues is a safe and effective alternative in mild/moderate uncomplicated DKA [ 13 ]. A Cochrane review evaluating 5 randomized controlled trials concluded that there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin for treating mild or moderate DKA [ 52 ]. Thus, amid the ongoing COVID-19 pandemic, subcutaneous insulin therapy can be an effective means of treating DKA while reducing ICU utilization, inadvertant exposure and PPE use.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have demonstrated that the use of subcutaneous rapid-acting insulin analogues is a safe and effective alternative in mild/moderate uncomplicated DKA [ 13 ]. A Cochrane review evaluating 5 randomized controlled trials concluded that there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin for treating mild or moderate DKA [ 52 ]. Thus, amid the ongoing COVID-19 pandemic, subcutaneous insulin therapy can be an effective means of treating DKA while reducing ICU utilization, inadvertant exposure and PPE use.…”
Section: Discussionmentioning
confidence: 99%
“…In light of trend toward greater cases of mild DKA, there might be increased opportunity to treat some DKA cases in the emergency room or short-term observation ward with subcutaneous insulin treatment [34], [35], [36], [37]. Further prospective studies are warranted for the feasibility and safety of this novel treatment in the setting of Asian patients.…”
Section: Discussionmentioning
confidence: 99%
“…76 Potential candidate patients include those who are alert and do not otherwise need admission to a critical care area, have a pH above 7.0, and bicarbonate of at least 10 mmol/L (≥10 mEq/L) 77. Four prospective randomized studies in adult patients with diabetic ketoacidosis compared subcutaneous rapid acting insulin (initial bolus of 0.3 units/kg followed by 0.1-0.2 units/kg every 1-2 hours) with conventional diabetic ketoacidosis treatment and found no difference in patient outcomes 77787980.…”
Section: Acute Managementmentioning
confidence: 99%